JP5936707B2 - インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法 - Google Patents

インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法 Download PDF

Info

Publication number
JP5936707B2
JP5936707B2 JP2014548825A JP2014548825A JP5936707B2 JP 5936707 B2 JP5936707 B2 JP 5936707B2 JP 2014548825 A JP2014548825 A JP 2014548825A JP 2014548825 A JP2014548825 A JP 2014548825A JP 5936707 B2 JP5936707 B2 JP 5936707B2
Authority
JP
Japan
Prior art keywords
group
formula
combination
andrographolide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500880A5 (enExample
JP2015500880A (ja
Inventor
オロスコ， フアン エレ． ハンク
オロスコ， フアン エレ． ハンク
ラファエル ブルゴス，
ラファエル ブルゴス，
Original Assignee
イノバイオサイエンス， エルエルシー
イノバイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5936707(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イノバイオサイエンス， エルエルシー, イノバイオサイエンス， エルエルシー filed Critical イノバイオサイエンス， エルエルシー
Publication of JP2015500880A publication Critical patent/JP2015500880A/ja
Publication of JP2015500880A5 publication Critical patent/JP2015500880A5/ja
Application granted granted Critical
Publication of JP5936707B2 publication Critical patent/JP5936707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014548825A 2011-12-21 2012-12-19 インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法 Active JP5936707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578650P 2011-12-21 2011-12-21
US61/578,650 2011-12-21
PCT/US2012/070568 WO2013096423A1 (en) 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis

Publications (3)

Publication Number Publication Date
JP2015500880A JP2015500880A (ja) 2015-01-08
JP2015500880A5 JP2015500880A5 (enExample) 2016-02-18
JP5936707B2 true JP5936707B2 (ja) 2016-06-22

Family

ID=48669439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548825A Active JP5936707B2 (ja) 2011-12-21 2012-12-19 インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法

Country Status (10)

Country Link
US (1) US9060994B2 (enExample)
EP (1) EP2670406B1 (enExample)
JP (1) JP5936707B2 (enExample)
AU (1) AU2012359081B2 (enExample)
BR (1) BR112014015178A2 (enExample)
CA (1) CA2853779C (enExample)
CL (1) CL2014001663A1 (enExample)
ES (1) ES2554459T3 (enExample)
RU (1) RU2014113967A (enExample)
WO (1) WO2013096423A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6928963B2 (ja) * 2016-06-08 2021-09-01 イノバイオサイエンス， エルエルシー アンドログラホリドが進化型の多発性硬化症を処置する
US11318153B2 (en) 2018-06-25 2022-05-03 Bialpha International Sdn. Bhd. Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function
CN109824655B (zh) * 2019-04-08 2021-09-24 沈阳药科大学 穿心莲内酯化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US6410590B1 (en) * 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US20050181033A1 (en) 2000-06-29 2005-08-18 Dekker John P.Iii Method for delivering interferons to the intradermal compartment
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
KR20070026398A (ko) 2004-02-03 2007-03-08 우니베르시다드 오스뜨랄 데 칠레 Ｐｐａｒ-감마 수용체의 활성화에 의한 자가면역 질환 및알츠하이머병의 치료에 유용한, 천심련으로부터 추출된랍단 디테르펜을 포함하는 조성물
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue

Also Published As

Publication number Publication date
CA2853779A1 (en) 2013-06-27
US9060994B2 (en) 2015-06-23
CA2853779C (en) 2016-04-26
RU2014113967A (ru) 2016-02-10
NZ625051A (en) 2016-07-29
WO2013096423A1 (en) 2013-06-27
ES2554459T3 (es) 2015-12-21
EP2670406B1 (en) 2015-09-02
AU2012359081A1 (en) 2014-06-05
EP2670406A1 (en) 2013-12-11
EP2670406A4 (en) 2014-05-28
CL2014001663A1 (es) 2015-02-27
BR112014015178A2 (pt) 2017-06-13
AU2012359081B2 (en) 2015-09-17
US20140301981A1 (en) 2014-10-09
JP2015500880A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
Virchow et al. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
KR20150003765A (ko) 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료
US20220362197A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
JP2020193206A (ja) 多発性硬化症を治療するためのクラドリビン投薬計画
EP2698167A2 (en) Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
US20210161836A1 (en) Treatment of demyelinating disorders
WO2006053172A2 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
Guo et al. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis
JP5936707B2 (ja) インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法
US20130203722A1 (en) Estriol therapy for autoimmune and neurodegenerative disease and disorders
WO2014011827A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
US20130202555A1 (en) Treatment of multiple sclerosis with masitinib
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
US20160030566A1 (en) Treatment of multiple sclerosis
KR102177781B1 (ko) 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
NZ625051B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Class et al. Patent application title: TREATMENT OF MULTIPLE SCLEROSIS WITH MASITINIB Inventors: Alain Moussy (Paris, FR) Alain Moussy (Paris, FR) Jean-Pierre Kinet (Lexington, MA, US) Jean-Pierre Kinet (Lexington, MA, US) Assignees: AB SCIENCE
NZ621215B2 (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140826

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140826

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20151218

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160510

R150 Certificate of patent or registration of utility model

Ref document number: 5936707

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250